z-logo
open-access-imgOpen Access
A Clinico-Pathological Study and Management of Parotid Tumours
Author(s) -
Raga Bhava Harshitha Kavali,
Nagarjun Nelluri,
Manmadha Kishan,
Kishore Chandra Prasad,
Anerudh Syamji,
Kokkonda Pavan Kumar
Publication year - 2021
Publication title -
sas journal of surgery
Language(s) - English
Resource type - Journals
ISSN - 2454-5104
DOI - 10.36347/sasjs.2021.v07i11.016
Subject(s) - medicine , parotid gland , pleomorphic adenoma , parotidectomy , incidence (geometry) , facial nerve , presentation (obstetrics) , complication , surgery , pathological , neoplasm , radiation therapy , salivary gland , radiology , pathology , physics , optics
Aim: The aim of the study is to know the incidence of parotid gland tumours with respect to age and sex, to study the various modes of clinical presentation of parotid tumours and to evaluate the various modes of surgery and outcome of surgical management of parotid gland tumours (both benign and malignant) at MRIMS, Hyderabad. Materials and methods: This study was conducted from July 2019 to July 2021 over a period of 2 years. 30 patients admitted in MRIMS with parotid gland neoplasm were included in this study. Inclusion criteria: All patients with parotid swelling due to parotid neoplasm were included. Exclusion criteria: All paediatric patients, patients with tumour like conditions and infectious causes of parotid gland were excluded. Results: The incidence of parotid tumours was highest in 3rd to 5th decade. Males were more affected than females. Majority of the tumours were benign in nature. All patients presented with swelling in parotid region (100%). Pain is always on account of malignant tumour. Pleomorphic adenoma was the commonest benign tumour. The treatment of choice of all benign tumours is superficial parotidectomy. All malignant tumours were subjected to post- operative radiotherapy. Commonest post-operative complication was facial nerve weakness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here